Explore by topic
What do you want to understand about living healthier for longer?
Five plain-language categories organize every published story. The category tells you where to browse; the evidence label tells you whether the story examines human outcomes, biomarkers, observational research or an early safety trial.
Exercise, sleep, eating patterns and other daily-life questions with human evidence.
Newest coverageStopping smoking was associated with lower mortality at every age studied
Browse all 55 stories in Latest
- LIFTMOR improved bone density in a small supervised trial—not fracture preventionHuman BMD and function · small supervised randomized trial
- Human time-restricted-eating trials show mixed short-term results—not slower agingHuman outcomes · short randomized trials
- Structured physical activity reduced late-life mobility disability—not aging itselfHuman function · randomized trials
- Sleep patterns are linked to healthy aging—but most evidence is observationalHuman outcomes · mostly observational evidence
- PREDIMED found fewer cardiovascular events after a Mediterranean-style diet—with a correction historyHuman clinical outcomes · corrected randomized trial
- CALERIE tested calorie restriction for two years—not human lifespanHuman outcomes and biomarkers · randomized trial
- Exercise has strong evidence for function—not proof of slower biological agingHuman function · mature randomized evidence
Medicines, experimental compounds and supplements—kept within the exact populations and outcomes studied.
Newest coverageSpermidine did not improve the trial’s primary memory outcome
Browse all 55 stories in Latest- Spermidine did not improve the trial’s primary memory outcomeHuman cognitive tests · randomized phase 2b trial
- Urolithin A missed both primary outcomes in older adultsHuman function and biomarkers · small randomized trial
- GlyNAC’s small trial cannot establish reversal of agingHuman biomarkers and function · very small randomized trial
- ASPREE found no gain in disability-free survival—and more major bleedingHuman function and safety · large randomized trial
- ASPREE did not lower cardiovascular events—and increased major bleedingHuman cardiovascular and safety outcomes · large randomized trial
- ASPREE’s cancer signal changed across longer follow-upHuman mortality and cancer outcomes · trial plus observational extension
- Vitamin D is essential. VITAL still found no broad prevention benefitHuman clinical outcomes · large randomized prevention trial
- Resveratrol has a longevity reputation. Human trials tell a mixed storyHuman biomarkers and cognitive tests · small heterogeneous trials
- Statin evidence changes with age, risk and prevention settingHuman clinical outcomes · trials and pooled evidence
- “Omega-3” is not one intervention—and the trial results do not transferHuman clinical outcomes · formulation-specific randomized trials
- Creatine added to resistance training may improve some strength measures—not longevityHuman function · trials and pooled evidence
- Semaglutide reduced cardiovascular events in SELECT—not agingHuman clinical outcomes · large randomized trial
- NAD precursors raise some metabolites; human longevity benefits remain unprovenHuman biomarkers · small trials
- Metformin is established for diabetes—not for extending healthy human lifeHuman biomarkers and muscle · small trials
- Human senolytic studies remain small safety and feasibility pilotsEarly human safety and feasibility · small pilots
- PEARL trial found no change in its main visceral-fat outcomeHuman outcomes · small randomized trial
1 story
Experimental biotechnology
Early technologies that may target aging biology but remain far from a demonstrated longevity treatment.
Biomarkers and tools that estimate age-related patterns without proving added healthy years.
Newest coverageCold-water studies measure thermogenesis—not longer life
Browse all 55 stories in Latest
- What an epigenetic clock can—and cannot—tell youBiomarker methods · human validation evidence
Aging-related outcomes such as mobility, cognition and independence.
Newest coverageSTRIDE did not significantly reduce serious fall injuries in primary care
Browse all 55 stories in Latest
- A colonoscopy invitation lowered cancer incidence—not mortality at 13 yearsHuman cancer incidence and mortality · large randomized invitation trial
- Low-dose CT reduced lung-cancer mortality in selected high-risk smokersHuman lung-cancer mortality · large randomized screening trial
- PSA screening lowered prostate-cancer mortality—and increased diagnosesHuman prostate-cancer mortality and diagnosis · long randomized screening follow-up
- TRAVERSE found cardiovascular noninferiority—not a longevity benefitHuman cardiovascular outcomes · large randomized noninferiority trial
- Testosterone did not prevent fractures in TRAVERSEHuman fracture and bone-density outcomes · randomized trials
- Testosterone’s walking result was modest—not an anti-aging effectHuman physical-function outcomes · one-year randomized trials
- Shingles vaccines prevent shingles. Dementia evidence remains non-randomizedHuman disease outcomes · randomized and non-randomized evidence
- High-dose flu vaccine reduced influenza—not immune agingHuman infection outcome · large randomized trial
- RSV vaccines reduce respiratory disease. Separate trials cannot rank themHuman respiratory outcomes · three randomized vaccine trials
- Menopausal hormone therapy treats symptoms. WHI did not show a longevity benefitHuman disease outcomes and mortality · randomized trials
- Zoledronic acid reduced fractures in osteoporosis—not aging itselfHuman fracture outcomes · large randomized trial
- Multivitamins moved some tests and aging clocks. What does that mean?Human cognitive tests and biomarkers · correlated randomized substudies
- SPRINT reduced cardiovascular events—not aging itselfHuman clinical outcomes · large randomized trial
- Hearing intervention did not slow cognitive decline across the full ACHIEVE trialHuman outcomes · randomized trial with subgroup signals
More to explore
Dig deeper into aging, treatments and human evidence.
MoreYears.news does not invent story counts for subjects that have not been reported yet. These reader guides provide useful context while coverage expands.
Why do our bodies age?
Explore cells, tissues, organ systems and comparative biology.
Explore Aging BiologyWhat are researchers testing?
Orient by lifestyle, drugs, supplements, biotechnology and measurement.
Explore InterventionsWhich outcomes matter?
Follow papers, trials, results, claims and their limitations.
Explore ResearchWhich signals deserve confidence?
Understand study design, biomarkers, safety and translation.
Open LearnStandalone coverage is still growing for immune aging, cancer and aging, brain aging, organ-specific aging, exceptional longevity and other roadmap subjects. They will become prominent only when real, reviewed stories exist.
Methods and transparency
Why you can trust the reporting.
Process details and non-medical product demonstrations remain available for readers who want them, outside the primary story path.